We advised Alkermes plc on its completed separation of its oncology business into Mural Oncology plc, a new, independent, publicly traded company on the Nasdaq Global Market under the stock ticker symbol “MURA”. Alkermes plc is now a pure-play neuroscience company and will continue to trade under the Nasdaq ticker symbol “ALKS.”

The team was led by Christopher McLaughlin (Corporate and M&A) and included Niamh O’Toole, Tim Gleeson, Susan O’Leary, Sinéad Corbett and Diarmaid Leahy (Corporate M&A), Fintan Clancy and Simona Prielaidaite (Tax), Olivia Mullooly, Ciara Anderson and Aoife Mac Ardle (Technology & Innovation), Kevin Langford (Employment), Kevin Lynch and Alexandra Hussain (Banking and Finance), and Ronan Scanlan (Competition and Regulated Markets).

Read more here.